TISSUE DONATION IS CRITICAL TO FIND TREATMENTS! Click here to learn more.
We envision a world where Epithelioid Hemangioendothelioma (EHE) is easily diagnosed and treatable. Join our dedicated community by subscribing to our emails.
EMPOWER YOURSELF WITH KNOWLEDGE
Upcoming Foundation Events
Quick Links
Patients
Community
Latest EHE News, Events and Research
The Pledge: Edition 42, Q3 – July-September, 2025
Publication of The Pledge quarterly newsletter is led by the EHE Rare Cancer Charity (UK). EHE patient advocacy groups from around the globe provide content including research news, patient and fundraising stories, and much more. Click here to view the most recent edition of the online EHE newsletter, The Pledge.
Read More
EHE Stabilization with Sirolimus: Results From POEM, a Prospective Multicentric Observational Study
Drs. Claudia Giani, Anna Maria Frezza, Silvia Stacchiotti, and colleagues from the Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy, and Royal Marsden Hospital, London, UK, presented results from POEM: a prospective observational study on Epithelioid Haemangioendothelioma at ESMO Congress 2025. The data presented included 57 consecutive molecularly confirmed EHE patients who entered the study, […]
Read More
Hanna Lab at Purdue University: ‘When cells in the body stop following the rules, cancer can take hold.’
You met Jason Hanna, PhD, at the 2025 EHE Global Patient Conference, where he highlighted work his lab is undertaking in EHE. We are thrilled to share a recent publication in Molecular Oncology from the Hanna Lab at Purdue University, highlighting their findings from a study focused on the YAP1-TFE3 subtype of EHE. The YAP1-TFE3 […]
Read More
Exciting Progress in EHE Research – Powered by Patients
We are thrilled to share a new publication, “EHE cell cultures are a platform for mechanistic and therapeutic investigation,” made possible by a partnership between the University of Iowa and the EHE Foundation. Under the leadership of Dr. Munir Tanas, Nicholas Scalora, PhD, and colleagues in the Tanas Lab sought to develop long-term EHE cell […]
Read More
Uniting for a Cure: A New Chapter in the Fight Against EHE
FOR IMMEDIATE RELEASE Hobart, WI – October 9, 2025 – The Center for Research and Analysis of VAscular Tumors (CRAVAT) Foundation has donated its resources to The EHE Foundation in a powerful alignment of vision and commitment to the people affected by epithelioid hemangioendothelioma (EHE) and the EHE scientific community. Founded in 2015 by Guy […]
Read More
Big Steve Day 2025: A Celebration of Life, Friendship, and Giving Back
On Saturday, June 28, 2025, more than 80 golfers, friends, and family gathered at Stony Creek Golf Course in Oak Lawn, Illinois, for the Third Annual Big Steve Day Golf Outing — a day filled with laughter, camaraderie, and purpose. This annual event honors the life and spirit of Steve Walsh, Jr., whose memory continues […]
Read More
The Pledge: Edition 35, Q4 – October-December, 2023
Publication of The Pledge quarterly newsletter is led by the EHE Rare Cancer Charity (UK). EHE patient advocacy groups from around the globe. provide content including research news, patient and fundraising stories, and much more! Click here to view the most recent edition of our online EHE newsletter, The Pledge.
Read More
Science Saturday: Patient-Powered Research
Join The EHE Foundation’s Director of Research, Denise Robinson, as she explains the power of patients to advance research into EHE. What is patient-powered research, why does it matter, and how can you contribute? Join us to learn what’s happening in EHE research and the pivotal role you play in advancing our understanding of this […]
Read More
IK-930 Receives Orphan Drug Designation for EHE
Ikena Oncology has shared that on December 14th, 2023, the Food and Drug Administration (FDA) granted Orphan Drug Designation to IK-930 for the treatment of epithelioid hemangioendothelioma (EHE). We are excited about this designation following initial positive data from the IK-930 Phase I clinical trial published in Ikena’s November 9th press release. What does this […]
Read More